Oracle Announces the Release of Oracle Argus Safety Suite 5.1
Oracle (Redwood Shores, CA) announced the release of Oracle Argus Safety Suite 5.1, its integrated pharmacovigilance suite that helps users meet regulatory compliance by supporting drug safety processes across the R&D spectrum, from clinical development through post-marketing.
The new release includes enhancements to Oracle Argus Safety (advanced reporting features, including dashboards and metrics, and new automation functionality for case processing), Oracle Argus Insight, and Oracle Argus Perceptive.
“Health sciences organizations recognize that they can significantly reduce the costs and risks associated with bringing drugs and devices to market by identifying and effectively managing safety issues early,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “The Oracle Argus Safety Suite has proven effective in helping organizations of all sizes ensure regulatory compliance and improve the overall safety of therapies.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
